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Let-7 is crucial for both stem cell differentiation and
tumor suppression. Here, we demonstrate a chro-
matin-dependent mechanism of let-7 in regulating
target gene expression in cancer cells. Let-7 directly
represses the expression of AT-rich interacting
domain 3B (ARID3B), ARID3A, and importin-9. In
the absence of let-7, importin-9 facilitates the nuclear
import of ARID3A, which then forms a complex with
ARID3B. The nuclear ARID3B complex recruits
histone demethylase 4C to reduce histone 3 lysine
9 trimethylation and promotes the transcription of
stemness factors. Functionally, expression of
ARID3B is critical for the tumor initiation in let-7-
depleted cancer cells. An inverse association be-
tween let-7 and ARID3A/ARID3B and prognostic
significance is demonstrated in head and neck can-
cer patients. These results highlight a chromatin-
dependent mechanism where let-7 regulates cancer
stemness through ARID3B.INTRODUCTION
The lethal-7 (let-7) microRNA (miRNA) family has been shown to
play a central role in development and cancer. During mamma-
lian embryonic development, let-7 is absent from embryonic
stem cells (ESCs) and is expressed later in development
(B€ussing et al., 2008). The introduction of let-7 to miRNA-defi-
cient ESCs rescues their compromised differentiation phenotype
(Melton et al., 2010), indicating an essential role of let-7 in ESC
differentiation. In cancer cells, let-7 acts as a major tumor sup-520 Cell Reports 14, 520–533, January 26, 2016 ª2016 The Authorspressor. A reduction in let-7 expression has been demonstrated
in different types of human cancer (Takamizawa et al., 2004;
Ruzzo et al., 2012; Marino et al., 2014). Mechanistically, let-7
exerts its tumor-suppressive effects by directly targeting various
oncogenes, including RAS (Johnson et al., 2005) and MYC
(Sampson et al., 2007). Emerging evidence indicates a crucial
role of let-7 in suppressing cancer stemness. A marked reduc-
tion in let-7 expression is observed in breast cancer stem cells
(CSCs), and antagonizing let-7 enhances CSC self-renewal
and tumorigenicity (Yu et al., 2007). Furthermore, let-7 represses
the migration of CSCs by targeting the Rac1 co-activators
NEDD9 and DOCK3 (Yang et al., 2012). Several key stemness
factors, such as high-mobility group AT-hook 2 (HMGA2) and
AT-rich interactive domain-containing protein 3B (ARID3B),
were shown to be targeted by let-7 (Mayr et al., 2007; Chien
et al., 2015). However, the sporadic suppression of genes is
insufficient to induce a global change in the gene expression pro-
file for a specific phenotype. We speculate that let-7 regulates
development and cancer stemness by globally regulating gene
expression in affected cells, rather than by solely targeting indi-
vidual transcripts.
Epigenetic reprogramming is a key event in regulating the self-
renewal of cancer cells and stem cells (Tee and Reinberg, 2014;
Dawson and Kouzarides, 2012). In cancer cells, epigenetic regu-
lation is critically involved in the induction of the epithelial-
mesenchymal transition (EMT) (Wu et al., 2012), a process that
is critical for generating CSCs (Mani et al., 2008). Specific chro-
matin modifiers, such as histone deacetylases and polycomb
group proteins, participate in the EMT through the epigenetic
regulation of target genes, resulting in a transcriptome shift in
the mesenchymal-like CSCs (Yang et al., 2010; McDonald
et al., 2011; Wu et al., 2011). The widespread presence of active
chromatin domains is a distinctive feature of ESCs (Azuara et al.,
2006). ESC differentiation is accompanied by global chromatin
remodeling, including the progressive distribution of the hetero-
chromatin marks histone 3 lysine 9 trimethylation (H3K9me3)
and histone 3 lysine 27 trimethylation (H3K27me3) near silenced
genes (Wen et al., 2009; Zhu et al., 2013). Given the previously
described impact of let-7 on cancer and development, it is
reasonable to assume that let-7 has a global effect on target
gene regulation through epigenetic mechanisms.
In this study, we demonstrate a chromatin-dependent mecha-
nism of let-7 in regulating target gene expression in cancer cells.
The ARID3B complex modulates the chromatin configuration of
stemness genes by recruiting histone demethylase 4C, which
facilitates gene transcription. Let-7 inhibits the formation of the
ARID3B complex thereby downregulates stemness genes in
cancer cells.
RESULTS
ARID3BExists at a Higher Hierarchical Level to Regulate
the Expression of Core let-7 Target Genes
The goal of the study is to identify the key regulator of let-7-
mediated target gene repression in cancer cells. First, we es-
tablished a platform to reduce let-7 expression for subsequent
experiments. To enrich for the stem-like population of cancer
cells (i.e., the sphere-derived cancer stem cells, SDCSCs),
sphere-forming cultures of two head and neck squamous cell
carcinoma (HNSCC) cell lines, FaDu and SAS, and a primary
culture of HNSCC cells were used (Hwang et al., 2014) (Fig-
ure S1A). Small RNA sequencing revealed significantly reduced
let-7 family miRNA expression levels in the FaDu-derived
SDCSCs compared with the parental cell line (Table S1A),
which were validated by qPCR (Figure S1B). Consistent with
these results, RNA sequencing of the colon cancer line HT29
also demonstrated a decreased let-7 expression level in the
SDCSCs (Table S1B). A reduction in let-7 miRNAs was also
shown in the CD44-positive HNSCC cells, which represents
the HNSCC stem-like population (Prince et al., 2007) (Figures
S1C and S1D).
Next, we identified the ‘‘core let-7 target genes’’ and investi-
gated their interaction with one another. We considered
HMGA2, ARID3B, c-Myc, and H-RAS as ‘‘core let-7 target
genes’’ (Figure 1A) because HMGA2 and ARID3B displayed
top-ranked scores in the in silico prediction systems (Tables
S2A–S2C), and H-RAS and c-Myc are well-recognized let-7 tar-
gets that exert profound effects on cancer cells (Johnson et al.,
2005; Sampson et al., 2007). Let-7i was selected as a represen-
tative let-7miRNA for further experiments due to its crucial role in
HNSCC (Yang et al., 2012). The stable expression of let-7i in
OECM1 cells, which harbor low endogenous levels of let-7i,
repressed the expression of all core targets, whereas the neutra-
lization of let-7i in FaDu cells, which harbor high endogenous
levels of let-7i, increased core target expression (Figure 1B).
As opposed to the abundant reports demonstrating the repres-
sive role of let-7 on the expression of H-RAS, c-Myc, and
HMGA2, the evidence regarding let-7-mediated ARID3B repres-
sion is limited. Therefore, we validated the effect of let-7 on
ARID3B. An inverse correlation between ARID3B and let-7 was
shown in HNSCC cells and cell lines from the NCI-60 panel (Fig-
ure S1E; Table S3). The transfection of let-7 family miRNAs intoCOECM1 cells repressed ARID3B expression, with let-7i most
effectively repressing ARID3B (Figure S1F). The 30 UTR reporter
assay confirmed the let-7i-mediated repression of ARID3B (Fig-
ure S1G). The overexpression of Twist1 and LIN28, molecules
that are upstream of let-7 and repress its expression (Yang
et al., 2012; Viswanathan et al., 2008), increased ARID3B expres-
sion (Figures S1H and S1I).
Next, we investigated whether hierarchical regulation exists
among the core let-7 target genes. In let-7i-neutralized FaDu
cells, the suppression of ARID3B repressed the expression of
other core target genes, and the effect was not obvious when
knocking down other core target genes (Figures 1C and S1J).
The ectopic expression of ARID3B in FaDu cells upregulated
the expression of the other core target genes, whereas the
CRISPR/Cas9-mediated depletion of ARID3B in OECM1 cells
reduced the levels of these targets (Figures 1D and S1K). An in-
verse correlation between the let-7i and ARID3B-regulated
gene signatures in HNSCC cells was shown by Gene Set
Enrichment Analysis (GSEA) (Figure 1E). Furthermore, the
ARID3B-upregulated genes, which were also induced by
HMGA2, HRAS, and c-Myc, displayed an inverse correlation
with let-7 (Figure 1F). Together, these results indicated that
ARID3B is the master regulator of let-7-mediated target gene
repression.
ARID3B Is Critical for the let-7-Regulated Cancer
Stemness
ARID3B, a transcriptional regulator, is a member of the AT-rich
interactive domain-containing protein family and functions
together with its fellow family member ARID3A to control
cellular differentiation and B cell development (Numata et al.,
1999; Kim et al., 2007; Webb et al., 2011). Emerging evidence
suggests that ARID3B is involved in cancer transformation and
stem-like properties (Kobayashi et al., 2006, 2013; Roy et al.,
2014; Chien et al., 2015), but the mechanism of this involve-
ment remains elusive. Here, we investigated whether ARID3B
is crucial for mediating the let-7-regulated cancer stemness.
First, we confirmed the effect of ARID3B in the induction of
cancer stemness. An increased level of ARID3B was observed
in the CD44-positive HNSCC cells (Figure 2A). A GSEA demon-
strated an association between the ARID3B-regulated signa-
ture and tumorigenesis (Figure 2B). The ectopic expression of
ARID3B in FaDu cells led to an enrichment of the CD44-positive
population and increased the sphere formation, colony forma-
tion, migration, and invasiveness of the cells. In contrast, the
knockdown of ARID3B in OECM1 cells repressed these effects
(Figures S2A–S2E). The ectopic expression of ARID3B pro-
moted the tumor initiating and tumor growth capabilities of
FaDu cells in vivo (Figure S2F; Table S4). Next, we knocked
down ARID3B in the let-7i-neutralized FaDu cells (Figure 2C).
The neutralization of let-7i in FaDu cells increased the popula-
tion of CD44-positive cells and promoted the sphere-formation
ability, colony-forming capacity, migration, and invasiveness as
expected. The knockdown of ARID3B subsequently abrogated
these effects (Figures 2D–2G). Importantly, suppression of
ARID3B attenuated the tumor initiating and tumor growth
capabilities of the let-7i-neutralized FaDu cells in vivo (Figures
2H and 2I; Table S4). Furthermore, rescuing ARID3B inell Reports 14, 520–533, January 26, 2016 ª2016 The Authors 521
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Figure 1. ARID3B Locates at a Higher Hierarchical Level to Regulate the Core Target Genes of let-7
(A) A flowchart for showing the identification of the core target genes of let-7.
(B) Left panel: western blot of ARID3B, HMGA2, c-Myc, and H-RAS in OECM1 cells stably transfected with a let-7i expression vector (OECM1-let7i) or a control
vector (OECM1-Vec) (left), and FaDu cells stably expressed a let-7i sponge vector (FaDu-spg-let7i) or a control vector (FaDu-spg-ctrl) (right). The number in-
dicates the independent stable cell lines. Right panel: relative let-7i expression in OECM1-let7i vs. OECM1-Vec (upper) and the let-7 reporter activity for indicating
the neutralizing effect in FaDu-spg-let7i versus FaDu-spg-ctrl (lower).
(C) qRT-PCR for examining the expression of the core target genes of let-7 (HMGA2, ARID3B, HRAS andMYC) in FaDu-spg-let7i cells receiving shRNA against
HMGA2, ARID3B, HRAS, and MYC versus a scrambled control (scr). The data represent fold changes of the expression of the core let-7 target genes after
knockdown of the indicated genes.
(D) Western blot (left) and qRT-PCR (right) of ARID3B, HMGA2, c-Myc, and H-RAS in FaDu cells stably transfected with ARID3B (FaDu-ARID3B) versus a control
vector (FaDu-Vec), and OECM1 cells depleted ARID3B by CRISPR/Cas9 (OECM1-ARID3B-Cas9) versus control (OECM1-ctrl).
(E) The GSEA result for analyzing the correlation between the let-7i expression (data obtained from cDNA microarray of OECM1-let7i versus OECM1-Vec) and
ARID3B signature (R4-fold upregulating in the cDNA microarray data of FaDu-ARID3B versus FaDu-Vec). ES, enrichment score; NES, normalized enrichment
score.
(F) Left: a flowchart for identification of the gene set regulated by the core let-7 target genes. The HMGA2/c-Myc/H-RAS signature was obtained by intersection of
the genes co-regulated by HMGA2/c-Myc/H-RAS. The data for HMGA2, c-Myc, and H-RAS signature were obtained from E-MEXP-2647, BILD_
MYC_ONCOGENIC_SIGNATURE, and BILD_HRAS_ ONCOGENIC_ SIGNATURE, respectively. Then, the genes upregulated R2-fold in FaDu-ARID3B were
intersected with the HMGA2/c-Myc/H-RAS-regulated genes to obtain the gene set regulated by the core let-7 target genes for GSEA analysis. Right: the GSEA
result for analyzing the correlation between the let-7i expression (data obtained from cDNA microarray of OECM1-let7i versus OECM1-Vec) and the gene set
regulated by the core let-7 target genes. ES, enrichment score; NES, normalized enrichment score.
For qRT-PCR in (B)–(D), data represent means ± SD. n = 3 independent experiments (each experiments contain two technical replicates). *p < 0.05, **p < 0.01.
See also Figure S1, Tables S1 and S2, and Table S3.
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Figure 2. ARID3B Is Critical in let-7-Regulated Stem-like Properties of HNSCC Cells
(A) Western blot of ARID3B in CD44-positive versus CD44-negative FaDu and OECM1 cells.
(B) The GSEA result for analyzing the correlation between the ARID3B-regulated signature of FaDu cells and the tumorigenesis gene expression profile of
Cromer’s dataset. ES, enrichment score. NES, normalized enrichment score.
(C)Western blot of ARID3B in FaDu cells receiving transfection of a let-7i sponge vector (FaDu-spg-let7i) or a control vector (FaDu-spg-ctrl) (left panel), and FaDu-
spg-let-7i receiving shRNA against ARID3B (sh-ARID3B) or a scrambled sequence (sh-scr).
(D) Flow cytometry of CD44 in FaDu-derived stable cell lines. The percentage of CD44-positive cells is shown in the right upper quadrant of each panel. Isotype
IgG was a control for flow cytometry.
(E) Spheroid formation assay. Upper, representative pictures of the spheroid in each stable clone. Scale bar, 100 mm. Lower, quantification of the secondary
spheres.
(F) Quantification of the soft agar colony formation assay in FaDu-derived stable clone. Cell dose, 5,000/each experiment.
(G) Fold changes of migration (left) and invasion (right) in FaDu and OECM1 clones.
(H) Representative photos for xenotransplantation assay. Cell dose, 1 3 103/each mouse. n = 5 for each group. Scale bar, 1 cm.
(I) The relative tumor weight of xenografted tumors. Data represent mean ± SD. *p < 0.05.
For (E)–(G), data represent mean ± SD. n = 2 independent experiments (each experiment contains three technical replicates). *p < 0.05.
See also Figure S2 and Table S4.
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Figure 3. ARID3B Correlates with the ESC Gene Expression Signature
(A) Heatmaps showing the expressions of ARID3B and pluripotency genes in ESCs versus differentiated cells (DC) (GSE2248), and in iPSCs versus human lung
fibroblast MRC-5 cell (GSE20750).
(B) qRT-PCR analysis of the expression of stemness genes in the human ESC cell line H9 receiving CRSPR/Cas9 for depleting ARID3B or control. Data represent
mean ± SD. n = 3 independent experiments (each experiments contain two technical replicates). *p < 0.05, **p < 0.01.
(C) Heatmaps showing the expressions of ARID3B and pluripotency genes in myeloid leukemia cells versus normal monocytes (N) (GSE3280), and in invasive
cancer cells versus normal pancreatic duct cells (N) (GSE19650).
(D) qRT-PCR for analyzing the expression of pluripotency genes in FaDu-ARID3B transfectants versus FaDu-vector control cells (FaDu-Vec) (left), and OECM1
cells receiving shRNA against ARID3B (OECM1-sh-ARID3B) versus a scrambled sequence (OECM1-sh-scr) (right). Red, upregulation; blue, downregulation. The
data shown are the mean value from three independent experiments.
(E) Gene ontology for analyzing the upregulated/downregulated genes in data obtained from the cDNA microarray of FaDu-ARID3B versus FaDu-vector control.
The cutoff value for upregulation,R2-fold; for downregulation,%0.5-fold.
(F) TheGSEA result for analyzing the correlation between the ARID3B-regulated signature of FaDu cells and the pluripotency gene expression profile of Boquest’s
dataset (upper), Bhattacharya’s dataset (middle), and Benporath’s dataset (lower). ES, enrichment score; NES, normalized enrichment score.
See also Figure S3 and Table S5.OECM1-let7i cells increased the CD44+ population and
enhanced migration, invasion, and colony-forming ability (Fig-
ures S2G–2J). These data suggest that ARID3B plays a crucial
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Because ARID3B regulates the stemness of cancer cells ex-
pressing low levels of let-7, and let-7 expression is minimal in
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Figure 4. ARID3A Is Another let-7 Target and Interacts with ARID3B
(A) The schema for identifying ARID3A as the let-7 target.
(B) 30 UTR reporter assay. Left: organization of theARID3A transcript. Right upper: schematic representation of the wild-type or let-7i binding site-mutated 30 UTR
reporter constructs of ARID3A (pMIR-ARID3A-WT and pMIR-ARID3A-Mut). Right lower: luciferase reporter assay. The result is shown as the fold changes of the
luciferase/b-galactosidase activity. Data represent mean ± SD. n = 2 independent experiments (each experiment contains three technical replicates).*p < 0.05.
(C) Western blot of ARID3A in OECM1 cells receiving transfection of different let-7 family miRNA mimics. Fold changes of ARID3A were shown for each
transfection.
(D) Western blot of ARID3A in OECM1 cells receiving transfection of a control vector (OECM1-Vec) versus a let-7 expression vector (OECM1-let7i) (upper panel),
and FaDu cells transfected with a let-7i sponge vector (FaDu-spg-let7i) versus a control vector (FaDu-spg-ctrl) (lower panel). The number indicates two inde-
pendent stable clones.
(E) Immunoprecipitation-western blot for detecting the association of endogenous ARID3B and ARID3A in OECM1 (upper) and SAS (lower) cells.
(F) Immunoprecipitation-western blot for detecting the interaction between wild-type/REKELSb-deleted (DR) ARID3A and ARID3B.
(legend continued on next page)
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ESCs (B€ussing et al., 2008), we hypothesized that ARID3B
expression is high in ESCs and that the ARID3B-expressing can-
cer cells harbor an ESC-like expression signature. We first deter-
mined the expression level of ARID3B in ESCs. By analyzing the
public database, we confirmed that the expression levels of
ARID3B and other stemness factors were increased in ESCs
and induced pluripotent stem cells (iPSCs) compared with differ-
entiated cells (Figure 3A; Tables S5A and S5B; Figure S3A).
ARID3B is located at the center of the ESC signaling network
(Figure S3B). Depletion of ARID3B in the H9 human ESC line
attenuated the expression of most pluripotency genes (Fig-
ure 3B). Next, we determined the signature of ARID3B-express-
ing cancer cells. Leukemic and invasive cancer cells exhibited a
higher level of ARID3B compared with their normal counterparts
(Figure 3C; Tables S5C and S5D). Overexpression of ARID3B in
FaDu cells increased the expression of the ESC factors including
Oct4, Nanog, and Sox2, while the knockdown or depleting
ARID3B in OECM1 cells suppressed them (Figures 3D, S3C,
and S3D). The re-expression of ARID3B in let-7i-depleted
OECM1 cells restored the expression of the pluripotency genes
(Figures S3E–S3G). Furthermore, compared with the suppres-
sion of other core let-7 target genes (HMGA2, c-Myc, and
H-RAS), the suppression of ARID3B exerted the most significant
effect on the inhibition of stemness gene expression (Fig-
ure S3H), confirming that ARID3B is located at a higher hierarchi-
cal level compared with the other let-7 targets. Gene ontology
analysis of the expression profile of the FaDu-ARID3B-trans-
fected cells showed a reduction in the development- and differ-
entiation-associated gene signatures, suggesting that ARID3B
maintains cancer cells in an undifferentiated state (Figure 3E).
The GSEA of FaDu-ARID3B versus control cells supported the
correlation between ARID3B and the ESC signature (Figure 3F).
Together, these data suggest a critical role of ARID3B in the
regulation of the ESC-like gene signature.
ARID3A Is Also a let-7 Target Gene and Interacts with
Nuclear ARID3B to Regulate the Expression of
Stemness Factors
We next reanalyzed the predicted let-7 target genes to identify
candidate(s) that may act cooperatively with ARID3B. Surpris-
ingly, ARID3A, which is an ARID family protein that interacts
with ARID3B (Kim et al., 2007), was identified as a candidate
let-7 target (Figure 4A). Let-7i repressed ARID3A expression by
binding to the 30 UTR of the ARID3A transcript (Figure 4B). The
expression of let-7 miRNAs repressed ARID3A expression,
with let-7i exerting the most prominent effect (Figure 4C). The(G) Immunofluorescence for detecting the impact of ARID3B on subcellular localiza
FaDu cells transfected with ARID3A or ARID3A+ARID3B. Red (rhodamine), ARID3
the ARID3A subcellular localization. N, nucleus; W, whole-cell staining; C, cytop
(H) Immunofluorescence for detecting the impact of REKLESb domain of ARI
immunofluorescent staining in FaDu cells co-transfected with ARID3B and HA-ta
ARID3B; blue, nuclei. Scale bar, 10 mm. Lower: quantification of the ARID3A su
independent experiments. *p < 0.05, **p < 0.01.
(I) Left upper: western blot for showing the expression of ARID3A in FaDu-spg-let7
blot for showing the reconstitution of wild-type ARID3A or ARID3A-DR. Right:
receiving shRNA against ARID3A (upper) and reconstituted with wild-type AIRD3
ments (each experiments contain two technical replicates). *p < 0.05, **p < 0.01.
See also Figure S4.
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expression, whereas the neutralization of let-7i in FaDu cells up-
regulated ARID3A (Figure 4D). Previous studies of ARID3 pro-
teins in the context of immunoglobulin gene regulation indicated
that ARID3B is consistently expressed in the nucleus while
ARID3A shuttles between the nucleus and the cytoplasm (Kim
and Tucker, 2006). Here, we investigated the interaction be-
tween ARID3A and ARID3B and the localization of the ARID3A-
ARID3B complex in HNSCC cells. We found that ARID3A and
ARID3B interacted with each other via the REKLESb domain
(Figures 4E and 4F). The ectopically expressed ARID3B trapped
ARID3A in the nucleus (Figure 4G). The deletion of the REKLESb
domain of ARID3A abolished the ARID3B-mediated nuclear
trapping of ARID3A (Figure 4H). The re-expression of wild-type
ARID3A has a higher effect in rescuing the expression of some
stemness-related genes (Oct4, Rex1, Lin28, and Sox2) than
REKLESb domain-deleted ARID3A in the ARID3A-depleted
FaDu-spg-let7i cells (Figure 4I). We further examined whether
ARID3B regulates the expression of ARID3A and the role of
ARID3A in regulating the expression of stemness factors. The
depletion of ARID3B fromOECM1 cells did not have a significant
impact on ARID3A expression (Figure S4A). The suppression of
ARID3A reduced the expression of the majority of the stem cell
factors that were examined. The double knockdown of both
ARID3A and ARID3B did not produce a significant additive effect
in the suppression of stemness gene expression (Figure S4B).
Collectively, these data suggest that both ARID3A and ARID3B
are let-7 targets and are critical for the regulation of stemness
gene expression in low-let-7 HNSCC cells and that the knock-
down of either one is sufficient to alter the expression of stem-
ness genes.
Importin-9, which Facilitates the Nuclear Import of
ARID3A, Is a let-7 Target
Exportin-1 has been reported to facilitate the nuclear export of
ARID3A (Kim and Tucker, 2006); however, the mechanism un-
derlying the nuclear import of ARID3A remains unclear. To deter-
mine whether let-7 influences the nuclear accumulation of
ARID3A by regulating its nuclear import or export, we first as-
sessed the impact of let-7 on exportin-1. However, the expres-
sion of exportin-1 was not affected by the modulation of let-7i
levels in HNSCC cells (Figure 5A). We next investigated the
impact of let-7 on importin proteins. Among the importin family
members, KPNA1, KPNA4, and IPO9, which encode impor-
tin-a5, importin-a3, and importin-9, respectively, are possible
candidates that harbor sequences complementary to let-7tion of ARID3A. Upper: representative photos of immunofluorescent staining in
A; white (Cy-5), ARID3B; blue, nuclei. Scale bar, 10 mm. Lower: quantification of
lasm. n = 3 independent experiments. *p < 0.05, **p < 0.01.
D3A on subcellular localization of ARID3A. Upper: representative photos of
gged wild-type/REKLESb domain-deleted (DR) ARID3A. Red, ARID3A; white,
bcellular localization. N, nucleus; W, whole-cell staining; C, cytoplasm. n = 3
i receiving ARID3A shRNA in the independent stable clones. Left lower: western
qRT-PCR for analyzing the expression of stemness genes in FaDu-spg-let7i
A/ARID3A-DR (lower). Data represent mean ± SD. n = 3 independent experi-
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Figure 5. let-7 Targets IPO9 to Reduce ARID3A Nuclear Localization
(A) Western blot of exportin-1 in FaDu cells receiving a let-7i sponge vector (FaDu-spg-let7i) versus a control vector (FaDu-spg-ctrl) (left), and OECM1 cells
transfected with let-7i expression vector (OECM1-let7i) versus a control vector (OECM1-Vec).
(B) The predicted seed regions of let-7 in the 30 UTR of the importin gene transcripts. Red font indicates the genes harboring seed regions of let-7.
(C) Western blot of importin-9, importin-a3, and importin-a5 in FaDu-spg-let7i versus control (left) and OECM1-let7 versus control (right).
(D) Upper: organization of the reporter constructs containing the wild-type or let-7i-binding sites-mutated 30 UTR of IPO9 (left), 30 UTR of KPNA4 (middle), or
KPNA1 (right). Lower: luciferase reporter assay. Data represent mean ±SD. n = 2 independent experiments (each experiments contain three technical replicates).
*p < 0.05.
(E) Immunoprecipitation-western blot for the association between importin-9 and ARID3A in 293T cells transfected with pHA-ARID3A with/without RanQ69L
treatment.
(F) Immunoprecipitation-western blot for the association between ARID3A and ARID3B in FaDu-ARID3B co-transfected with RanQ69L or a control vector.
(legend continued on next page)
Cell Reports 14, 520–533, January 26, 2016 ª2016 The Authors 527
(Figure 5B). The overexpression of let-7i in OECM1 cells
repressed the expression of importin-9 but did not alter the
expression of importin-a5 or importin-a3. Consistent with this,
the neutralization of let-7i in FaDu cells upregulated importin-9
but did not alter the expression of the other two importins (Fig-
ure 5C). The 30 UTR reporter assay further confirmed that, unlike
KPNA1 and KNPA4, IPO9 is a let-7 target (Figure 5D). We next
investigated whether importin-9 mediates the nuclear import of
ARID3A. Because Ran-GTP regulates the binding and release
of import/export receptor cargo in their respective target com-
partments (Nachury and Weis, 1999), immunoprecipitation was
performed to investigate the interaction between ARID3A and
importin-9 in the presence or absence of the dominant-negative
mutant Ran (RanQ69L), which is incapable of GTP hydrolysis
(Nachury and Weis, 1999). ARID3A co-immunoprecipitated
with importin-9 in the absence of RanQ69L. The addition of
RanQ69L disrupted the interaction between ARID3A and impor-
tin-9 (Figure 5E). The mutant Ran also disrupted the interaction
between ARID3A and ARID3B, suggesting a critical role of
ARID3A import in the formation of the ARID3A-ARID3B complex
(Figure 5F). A fluorescence recovery after photobleaching
(FRAP) assay confirmed that the rate of ARID3A transport is
significantly reduced after the knockdown of importin-9 (Fig-
ure 5G). The suppression of importin-9 reduced the nuclear
localization of ARID3A in FaDu-ARID3B (Figure 5H). Taken
together, these findings suggest that importin-9, which regulates
the nuclear import of ARID3A, is a let-7 target.
The ARID3B Complex Modulates the Histone 3 Lysine 9
Trimethylation at Stemness Genes
Wenext investigated whether the ARID3B complex regulates the
expression of target genes via epigenetic regulation because
certain ARID proteins are known to act as histone modifiers (Wil-
son and Roberts, 2011). First, we confirmed the ARID3B com-
plex occupancy of the AT-rich regions of various stemness
genes in the FaDu-ARID3B-transfected cells (Figure 6A). The
depletion of ARID3B reduced its occupancy of the regulatory re-
gions of POU5F1 and DPPA2 (Figure S5A). A sequential chro-
matin immunoprecipitation (ChIP) assay confirmed the ARID3A
and ARID3B co-occupancy of the POU5F1 promoter in
OECM1 cells. The knockdown of ARID3B inhibited this co-occu-
pancy (Figure 6B). We next examined whether the ARID3B com-
plex affects the histone modifications at stemness genes. The
overexpression of ARID3B in FaDu cells reduced the global level
of the heterochromatin marks histone 3 lysine 9 trimethylation
(H3K9me3) and histone 3 lysine 27 trimethylation (H3K27me3)
without exerting a significant effect on other histone marks.
The knockdown of ARID3B in OECM1 cells exerted the reverse
effect (Figure S5B). We next confirmed the effect of ARID3B on
various histone marks at the regulated genes. Among the exam-(G) Fluorescence recovery after photobleaching (FRAP) assay. Left, construction
fluorescence intensity at different time points in importin-9 knockdown 293T cells
(each experiments contain five technical replicates). *p < 0.05.
(H) Immunofluorescence for showing the impact of importin-9 knockdown on subc
of FaDu-ARID3B cells receiving shRNA against IPO9 or a control sequence (sh
ARID3B; blue, nuclei. Scale bar, 10 mm. Lower: quantification of the ARID3A loc
experiments. *p < 0.05, **p < 0.01.
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ARID3B expression. The ectopic expression of ARID3B in
FaDu cells reduced H3K9me3 levels at the regulatory regions
of POU5F1 and DPPA2, whereas the knockdown of ARID3B in
OECM1 cells increased H3K9me3 levels (Figure 6C). For
H3K27me3, the overexpression of ARID3B reduced
H3K27me3 levels; however, suppression of ARID3B only has a
minor effect in increasing H3K27me3 levels at the POU5F1 and
DPPA2 promoters (Figure S5C). ARID3B did not exert a consis-
tent effect on levels of H3K4me3, H3K4Ac, and H3K9Ac at the
target gene promoters (Figure S5D). The depletion of ARID3B
reduced Pol II recruitment to the regulated genes, indicating a
role of ARID3B in the transcriptional regulation of target genes
(Figure S5E). Co-immunoprecipitation assay that ARID3B inter-
acted with the histone demethylases KDM4C, KDM4D, and
KDM6B (Figure 6D). An increased KDM4C occupancy of the
promoter of pluripotency genes was observed in the ARID3B-
overexpressing FaDu cells, whereas the short hairpin RNA
(shRNA)- or CRISPR/Cas9-mediated suppression of ARID3B in
OECM1 cells reduced the KDM4C occupancy of the promoter
regions (Figure 6E; Figure S5F). A sequential ChIP assay
confirmed that ARID3B recruits KDM4C to the regulatory regions
of pluripotency genes (Figure 6F; Figure S6A). Importantly, the
ARID3B and KDM4C co-occupancy of the regulatory regions
of the core let-7 target genes HMGA2, MYC, and HRAS was
confirmed (Figure 6G). ARID3B preferentially bound to
H3K9me3 compared with H3 that was not methylated at lysine 9
(Figure 6H). An in vitro demethylation assay showed that the
ARID3B-containing nuclear extracts exhibited higher demethy-
lase activity for H3K9me3 (Figure S6B). An analysis of the public
data showed a negative association between the levels of
KDM4C and H3K9me3 at the regulatory regions of stemness
genes in mouse ESCs and mouse embryonic fibroblasts (Fig-
ure S6C). ChIP sequencing in OECM1 cells showed that ARID3B
and KDM4C were co-enriched at stemness genes and that the
depletion of ARID3B reduced the KDM4C occupancy at the
regulated genes (Figure S6D). We confirmed the effect of
ARID3B-mediated alterations in chromatin configuration in the
let-7-modified HNSCC cells. In OECM1 cells, transfection of
let-7i to OECM1 led to a reduced KDM4C occupancy of and
increased levels of H3K9me3 and H3K27me3 at the regulatory
regions of target genes. On the contrary, the neutralization of
let-7i in FaDu cells increased KDM4C binding and levels of
H3K9me3 and H3K27me3 at the regulated genes (Figure S6E).
The knockdown of KDM4C in the let-7i-neutralized FaDu cells
did not affect ARID3A and ARID3B expression; however, the up-
regulation of target genes and stemness genes mediated by the
neutralization of let-7i was attenuated by the knockdown of
KDM4C (Figure S6F). The above data support a chromatin-
dependent regulation of let-7 target genes in HNSCC cells.of the importin-9 knockdown 293T cells. Right, quantification of the nuclear
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Figure 6. ARID3B Complex Recruits KDM4C for Demethylating H3K9me3 at Target Genes
(A) ChIP assay in FaDu-ARID3B. Upper, schema of the regulatory regions of the stemness genes (POU5F1, DPPA2, ZNF206, ESG1, and FOXD3) and the ChIP/
control primers for experiments. Lower, ChIP assay. Signals amplified by the ChIP primers (left) or the control primers (right).
(B) ChIP and sequential ChIP for analyzing the co-occupancy of ARID3A and ARID3B on POU5F1 promoter in OECM1 cells receiving shRNA against ARID3B
(OECM1-sh-ARID3B) or a scrambled sequence (OECM1-sh-scr).
(C) Quantitative ChIP for analyzing the enrichment of H3K9me3 atPOU5F1 (left) andDPPA2 (right) in FaDu-ARID3B versus FaDu-vector control (FaDu-Vec) (upper
panels), and OECM1-sh-ARID3B versus OECM1-sh-scr (lower panels).
(D) Immunoprecipitation-western blot for detecting the association between ARID3B and the histone demethylases in the chromatin lysates obtained from
OECM1 (left) and SAS (right) cells.
(E) Quantitative ChIP to analyze the occupancy of KDM4C at POU5F1 (left) and DPPA2 (right) in FaDu-ARID3B versus FaDu-Vec (upper panels), and OECM1-sh-
ARID3B versus OECM1-sh-scr (lower panels).
(F) ChIP and sequential ChIP to analyze the co-occupancy of ARID3B and KDM4C on POU5F1 promoter in FaDu-ARID3B versus FaDu-Vec and OECM1-sh-
ARID3B versus OECM1-sh-scr.
(legend continued on next page)
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The Prognostic Impact of ARID3B in Various Types of
Cancer
We next confirmed the existence of the let-7-ARID3B axis and
the prognostic significance of ARID3B in various types of cancer.
An inverse correlation between let-7 and ARID3A/ARID3B was
shown in acute myeloid leukemia and lymphoma cell lines (Fig-
ure S7A). By analyzing the clinical data in The Cancer Genome
Atlas (TCGA), both ARID3A and ARID3B were upregulated in
head and neck cancers (Figure 7A). We then examined the
expression levels of POU5F1, ARID3A, ARID3B, and let-7
miRNAs in 43 samples collected from HNSCC patients at the
Taipei Veterans General Hospital of Taiwan (the characteristics
of these patients are shown in Table S6). A negative correlation
was found between the expression of let-7i and that of ARID3B
and ARID3A (Figure 7B). Positive correlations between the
expression of ARID3B and ARID3A or the pluripotency genes
POU5F1/NANOG were verified (Figure 7C). Moreover, negative
correlations were observed between additional let-7 miRNA
family members and both ARID3B and ARID3A (Figures S7B
and S7C). We also analyzed the levels of ARID3A and ARID3B
via immunohistochemistry (IHC) in samples collected from 129
HNSCC cases at the Taipei Veterans General Hospital (for pa-
tient characteristics, see Table S7; representative photos are
shown in Figure 7D). A high nuclear expression of ARID3B signi-
ficantly correlatedwith nuclear ARID3Aaccumulation (Figure 7E).
The co-expression of ARID3A and ARID3B in the nucleus corre-
lated with a poor outcome (Figure 7F). The prognostic signifi-
cance of ARID3B was also demonstrated in blood, brain, breast,
and skin cancers (data obtained from PrognoScan; Figure 7G).
DISCUSSION
In this study, we demonstrate the role of let-7 in the chromatin
modulation-mediated silencing of stemness factors and cano-
nical let-7 target genes (originally known to be regulated by
direct targeting). These observations suggest that let-7 regulates
the tumor-initiating capability of cancer cells via both the canon-
ical effects of miRNAs through the direct targeting of the tran-
scription of oncogenes, and the non-canonical effects of
miRNAs through modulation of the chromatin configuration of
target genes. The suppression of KDM4C activity is a potential
strategy for inhibiting cancer stemness in let-7-deficient or
ARID3B-overexpressing cancer cells.
Compared with the major stemness factors, the roles of
ARID3B and ARID3A in CSCs are relatively unclear. Here, we
focus on the effect of the ARID3B complex in regulating let-7
target genes and stemness factors. However, ARID3B-mediated
chromatin remodeling may have a global impact on the tran-
scription of a broad spectrum of target genes in addition to its
effects on let-7 target genes and stemness genes. Further inves-
tigation of the effects of ARID3B on the modulation of the chro-(G) ChIP and sequential ChIP for detecting the co-occupancy of ARID3B and KDM
for depleting ARID3B or control.
(H) Peptides binding assay. The biotin-labeled H3 or H3K9me3 peptides were
A competition assay was performed by adding the unlabeled H3K9me3 peptides
For (C) and (E), data represent mean ± SD. n = 3 independent experiments (each
and S6.
530 Cell Reports 14, 520–533, January 26, 2016 ª2016 The Authorsmatin configuration of non-let-7 target genes will be essential for
elucidating the comprehensive role of ARID3B in cancer cells.
Regarding ARID3A, we demonstrate that the downregulation of
let-7 facilitates the nuclear localization of ARID3A, which inter-
acts with ARID3B to regulate target gene expression. A recent
study showed that ARID3A translocates to the nucleus and
acts as both a repressor and an activator in trophoblasts, sug-
gesting that the activity of ARID3A is determined by its interac-
tion partner (Rhee et al., 2014). Whether ARID3A can function
as a repressor in CSCs to regulate a distinct set of target genes
via interactions with alternative partners remains to be
determined.
In conclusion, our study demonstrated a chromatin-depen-
dent mechanism of let-7 in the regulation of cancer stemness.
These results not only extend the current understanding of
let-7 in target gene regulation, but they also provide valuable in-
formation for the future development of strategies to inhibit can-
cer stemness.
EXPERIMENTAL PROCEDURES
miRNA Target Prediction and 30 UTR Luciferase Reporter Assay
The target genes of let-7 were predicted using PicTar and TargetScan 5.2. The
full-length 30 UTRs of ARID3B and ARID3Awere cloned into pMIR-REPORTER
to generate the pMIR-ARID3B-wt and pMIR-ARID3A-wt constructs, respec-
tively. The putative let-7i binding site was mutated to generate the pMIR-
ARID3B-mut and pMIR-ARID3A-mut plasmids. To clone the reporter
constructs for IPO9, KPNA1, and KPNA4, the 30 UTR containing the let-7
seed regions of these genes were cloned into pMIR-REPORTER to generate
the wild-type reporters, and the let-7 binding sites were mutated to generate
the mutant reporters (Figure 5D). A plasmid expressing the bacterial b-galac-
tosidase gene (pCMV-bGal) was co-transfected into cells as a control for the
transfection efficiency. The cells were harvested 48 hours after transfection,
and the luciferase activity was assessed. The relative reporter activities are
expressed as the fold changes in luciferase activity after normalization to
b-galactosidase activity.
In Vivo Limiting Dilution Assay
All procedures were conducted in accordancewith the institutional animal wel-
fare guidelines of the Taipei Veterans General Hospital. The 6- to 8-week-old
female BALB/c nude mice were purchased from the National Laboratory Ani-
mal Center of Taiwan. The number of mice used for each experiment is indi-
cated in the relevant figures. For the limiting dilution assays, the dissociated
cells were suspended in 50 ml of DMEM/F12 at the indicated densities and
mixed with an equal volume of Matrigel (Invitrogen). The mixtures were subcu-
taneously injected into the flanks ofmice, and themicewere sacrificed 8weeks
after inoculation with the tumor cells. The tumor weights were measured after
harvesting the xenotransplanted tumors.
ChIP and Sequential ChIP
The cells were cross-linked with 1% formaldehyde and then harvested. The
nuclear fractions were resuspended and subjected to sonication, and the
lysates were then incubated with protein A+G beads conjugated to specific
antibodies against different proteins or to an immunoglobulin G (IgG) control
antibody. The DNA-protein complexes were then eluted, and the specific re-
gions were amplified by PCR. For sequential ChIP, the supernatant was4C on the promoter of HRAS,MYC, and HMGA2 in OECM1 receiving CRISPR
incubated with the ARID3B immunoprecipitates obtained from OECM1 cells.
.
experiments contain two technical replicates). *p < 0.05. See also Figures S5
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Figure 7. ARID3B Overexpression Correlates with a Worse Prognosis of Human Cancers
(A) Analysis of the ARID3A and ARID3B mRNA level in normal versus tumor parts of HNSCC. The data were obtained from TCGA. *p < 0.05, **p < 0.01.
(B and C) qRT-PCR to analyze the expression of let-7i, ARID3A, and ARID3B (B) and ARID3B, ARID3A, POU5F1, and NANOG (C) in 43 HNSCC samples from
Taipei Veterans General Hospital. The high level (ARID3AHigh/ARID3BHigh) indicates the expression higher than mean value, whereas the low level (ARID3ALow/
ARID3BLow) indicates the expression lower than mean value. The boxplots represent sample maximum (upper end of whisker), upper quartile (top of the box),
median (band in the box), lower quartile (bottom of the box), and sample minimum (lower end of whisker).
(D) Representative immunohistochemical staining in HNSCC samples. Case 1, high ARID3B expression + ARID3A whole-cell expression; case 2, high ARID3B +
nuclear ARID3A; case 3, high ARID3B + cytoplasmic ARID3A; case 4, negative expression of both ARID3A and ARID3B. Scale bar, 200 mm.
(E) Analysis of the correlation between ARID3B expression and nuclear ARID3A in HNSCC samples. C, cytoplasmic expression; W, whole-cell expression;
N, nuclear expression; Neg, negative.
(F) Kaplan-Meier analysis of overall survival in 129 HNSCC patients with or without coexpression of ARID3B and nuclear ARID3A.
(G) Kaplan-Meier analysis of overall survival in different cancer patients with high versus low ARID3B expression. The data were obtained from PrognoScan and
the GSE number is shown in each panel.
See also Figure S7 and Tables S6 and S7.
Cell Reports 14, 520–533, January 26, 2016 ª2016 The Authors 531
collected, diluted 1:500 in IP buffer, and subjected to the IP procedure again,
and the regions of interest were then amplified.
Patient Samples and IHC
This study was approved by the Institutional Review Board of the Taipei Veter-
ans General Hospital. The HNSCC patient samples were collected at the Tai-
pei Veterans General Hospital between January 2007 and December 2012.
Forty-three frozen samples were collected for qRT-PCR analysis, and 129
formalin-fixed samples were used for IHC. The IHC results were independently
scored by two individuals. For ARID3B, >50% nuclear expression was consid-
ered positive, whereas cases of both nuclear and cytoplasmic ARID3A positive
expression (>50%) were documented.
Statistical Analysis
The numerical results are presented as the means ± SD. The samples whose
values were greater than two SDs from the mean were considered outliers and
were excluded from the analysis. A two-tailed independent Student’s t test
was used to compare the continuous variables between the two groups. The
chi-squared test was applied to compare dichotomous variables. The
Kaplan-Meier estimation and the log-rank test were used to compare survival
between the patient groups. All statistical data were derived from at least two
independent biological replicates, and each experiment contained at least two
technical replicates. The level of statistical significance was set to p% 0.05 for
all of the tests.
ACCESSION NUMBERS
The SuperSeries number GEO: GSE66603 contains three datasets, including
the ChIP-seq data for the OECM1-ARID3B-Cas9 and the control cells (GEO:
GSE66601), the cDNA microarray data for the FaDu-ARID3B and the control
cells (GEO: GSE66602), and the cDNA microarray data for the OECM1-let7i
and the control cells (GEO: GSE65789). The accession number for the FaDu
parental cells/FaDu-spheres small RNA-seq is GEO: GSE64422, and the
accession number for the HT29 parental cells/HT29-spheres small RNA-seq
is GEO: GSE43802
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